Merck's Welireg and Keytruda combo receives FDA approval for adjuvant kidney cancer therapy

Merck announced that its combination of the oral VEGFR inhibitor Welireg and the immunotherapy Keytruda has been cleared by the U.S. Food and Drug Administration.

The clearance applies to patients who have undergone partial or total nephrectomy for renal cell carcinoma, positioning the regimen as an adjuvant option to reduce the risk of disease recurrence.

The approval follows clinical data that demonstrated improved disease‑free survival compared with placebo, supporting the use of targeted therapy together with checkpoint inhibition in the post‑surgical setting.

The decision adds another indication for both drugs and expands Merck’s portfolio in oncology, potentially influencing treatment guidelines and market dynamics.